Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 20.80% +5.81, Ginkgo Bioworks ...

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...